G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$7.08 USD
-0.01 (-0.14%)
Updated Aug 13, 2024 04:00 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 141 - 160 ( 357 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
GTHX Activating a Supplemental Sales Strikeforce for COSELA
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Possible Incremental Return in Revenue with In-House Sales Force
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Cosela Growing Steadily in Q2, NTAP Should Fuel Q4.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
2Q21: COSELA Sales Improve Sequentially and Should Do so in Q3 and Q4.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
FDA Grants Fast Track Designation for Cosela in Combination With Chemo for Locally Advanced or mTNBC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Continued Execution to Expand COSELA Beyond Lung Cancer
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Highlights From Non-Deal Roadshow With G1 Therapeutics
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Therapeutics Initiates the Phase 2 PRESERVE 3 Study of Cosela in Bladder Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Updated Data for Rintodestrant in Combination With Ibrance for ER+/HER2- Advanced Breast Cancer at ASCO 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Update on Rintodestrant and Trilaciclib Presented at ASCO 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T